Tearlab Corp (TEAR): Brock Wright , director of Tearlab Corp purchased 130,314 shares on May 24, 2016. The Insider buying transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.76 per share for a total value of $98,531.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Wes Brazell (CFO) purchased 66,666 shares at $0.00 per share price.On May 11, 2016, Richard L Md Lindstrom (director) purchased 133,332 shares at $0.00 per share price.Also, On May 11, 2016, Joseph Jensen (CEO) purchased 133,332 shares at $0.00 per share price.On May 11, 2016, Anthony E Altig (director) purchased 33,334 shares at $0.00 per share price.
TearLab Corp: On Wednesday, May 25, 2016 heightened volatility was witnessed in TearLab Corp which led to swings in the share price. The shares opened for trading at $0.77 and hit $0.8099 on the upside , eventually ending the session at $0.7899, with a gain of 2.58% or 0.0199 points. The heightened volatility saw the trading volume jump to 1,07,198 shares. The 52-week high of the share price is $3.0299 and the company has a market cap of $27 M . The 52-week low of the share price is at $0.5995.
Company has been under the radar of several Street Analysts.TearLab Corp is Upgraded by Feltl & Co. to Strong Buy. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 5, 2016.
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company is engaged in commercial manufacturing of the TearLab Osmolarity System. The Company’s wholly owned subsidiary TearLab Research Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries metabolites (glucose) genes and proteins) at the point-of-care. The TearLab Osmolarity System measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System is an integrated testing system consisted of: the TearLab disposable the TearLab Pen and the TearLab Reader.